AstraZeneca is a big UK pharmaceutical company.

What is Bristol Myers Squibb?

Bristol Myers Squibb is a US pharmaceutical company.

A megadeal is a very big business deal, often worth hundreds of billions of dollars.

● ImportantEconomy1 outlet covering thisCalibrating

AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

First publishedAug 2, 20:12 UTC

Last updatedAug 2, 21:59 UTC · 13m ago

1 outlets over time — hover a bar for its window & outletslast updated

● Story signals

How strong is this topic?

6.5/10Significanceimpact & urgency

7.0/10Source trustoutlet authority

1Outletsindependent sources

Significance weighs impact, urgency & coverage breadth · Source trust is the outlets' average authority · more outlets means a more confirmed story.

Answer

AstraZeneca is in talks to merge with Bristol Myers Squibb in a $400 billion deal.

Reported by 1 outlet — CNBC Top News. See all sources ↓

AstraZeneca, a big UK pharmaceutical company, is talking about a big deal with Bristol Myers Squibb, a US company. The deal could be worth $400 billion. This is a very big business deal.

Why it matters

This deal could be very important for the pharmaceutical industry and the companies involved.

In brief

What is AstraZeneca?: AstraZeneca is a big UK pharmaceutical company.
What is Bristol Myers Squibb?: Bristol Myers Squibb is a US pharmaceutical company.
What is a megadeal?: A megadeal is a very big business deal, often worth hundreds of billions of dollars.

Different angles across outlets

Coverage map

How outlets are framing the same story

These are the main editorial angles found across reporting. Use them to quickly compare what different outlets emphasize, omit, or question.

All outlets report the same basic information about the potential deal, but do not provide additional context or analysis.

Coverage cardFraming signal
1Angle
Scouting report
AstraZeneca and Bristol Myers Squibb are considering a big business deal.
Sources1
TypeAngle
CNBC Top NewsAug 2, 20:12reports on the potential deal without additional context